

Genome Canada 2012 LSARP Pre-application [PI:Turecki & Kennedy]  
Reference List

1. Parikh, S.V., *et al.* Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. *J Affect Disord* **117 Suppl 1**, S15-25 (2009).
2. Robins, L.N. & Regier, D.A. *The Epidemiologic Catchment Area - Psychiatric disorders in America* (The Free Press, New York, 1991).
3. Narrow, W.E., Rae, D.S., Robins, L.N. & Regier, D.A. Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys' estimates. *Arch Gen Psychiatry* **59**, 115-123 (2002).
4. Regier, D.A., *et al.* One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites. *Arch Gen Psychiatry* **45**, 977-986 (1988).
5. Weissman, M.M. & Boyd, J.H. The epidemiology of affective disorders: rates and risk factors. in *Psychiatry update. The American Psychiatric Association annual review* (ed. R.E. Hales & A.J. Frances) 406-434 (American Psychiatric Press, Washington, 1983).
6. Murray, C.J.L. & Lopez, A.D. *The global burden of disease* (WHO, Geneva, 1998).
7. Pincus, H.A., *et al.* Prescribing Trends in Psychotropic Medications: Primary Care, Psychiatry, and Other Medical Specialties. *JAMA* **279**, 526-531 (1998).
8. Bantnin, J.S. & Miller, G.E. Trends in prescription drug expenditures by Medicaid enrollees. *Medical care* **44**, 127-35 (2006).
9. Chen, Y., *et al.* Utilization, price, and spending trends for antidepressants in the US Medicaid Program. *Res Social Adm Pharm* **4**, 244-257 (2008).
10. Trivedi, M.H., *et al.* Evaluation of outcomes with citalopram for depression using measurement-based care in STAR\*D: implications for clinical practice. *Am J Psychiatry* **163**, 28-40 (2006).
11. Berlim, M.T., Fleck, M.P. & Turecki, G. Current trends in the assessment and somatic treatment of resistant/refractory major depression: an overview. *Ann Med* **40**, 149-159 (2008).
12. Berlim, M.T. & Turecki, G. What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials. *Eur Neuropsychopharmacol* **17**, 696-707 (2007).
13. Berlim, M.T. & Turecki, G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. *Can J Psychiatry* **52**, 46-54 (2007).
14. Serretti, A., Kato, M., De Ronchi, D. & Kinoshita, T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. *Molecular psychiatry* **12**, 247-257 (2007).
15. Serretti, A., *et al.* Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. *Eur Neuropsychopharmacol* **11**, 375-380. (2001).
16. Serretti, A., *et al.* Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. *Mol Psychiatry* **6**, 586-592. (2001).
17. Arias, B., *et al.* Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. *J Affect Disord* **90**, 251-256 (2006).
18. Szegedi, A., *et al.* The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. *Pharmacogenomics J* **5**, 49-53 (2005).
19. Baune, B.T., *et al.* Association of the COMT val158met variant with antidepressant treatment response in major depression. *Neuropsychopharmacology* **33**, 924-932 (2008).

20. Yoshida, K., *et al.* Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran. *Hum Psychopharmacol* **23**, 121-128 (2008).
21. Zill, P., *et al.* Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment. *Neuroreport* **11**, 1893-1897. (2000).
22. Lin, K.M. Biological differences in depression and anxiety across races and ethnic groups. *J Clin Psychiatry* **62 Suppl 13**, 13-19; discussion 20-11 (2001).
23. Serretti, A., *et al.* Serotonin transporter gene (5-HTTLPR) and major psychoses. *Mol Psychiatry* **7**, 95-99 (2002).
24. Serretti, A., *et al.* SSRIs antidepressant activity is influenced by G beta 3 variants. *Eur Neuropsychopharmacol* **13**, 117-122 (2003).
25. Rasenick, M.M., Chaney, K.A. & Chen, J. G protein-mediated signal transduction as a target of antidepressant and antibipolar drug action: evidence from model systems. *J Clin Psychiatry* **57 Suppl 13**, 49-55; discussion 56-48 (1996).
26. Dwivedi, Y. Brain-derived neurotrophic factor: role in depression and suicide. *Neuropsychiatric disease and treatment* **5**, 433-449 (2009).
27. Molendijk, M.L., *et al.* Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. *Molecular psychiatry* **16**, 1088-1095 (2011).
28. Tsankova, N.M., *et al.* Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. *Nat Neurosci* **9**, 519-525 (2006).
29. Onishchenko, N., Karpova, N., Sabri, F., Castren, E. & Ceccatelli, S. Long-lasting depression-like behavior and epigenetic changes of BDNF gene expression induced by perinatal exposure to methylmercury. *J Neurochem* **106**, 1378-1387 (2008).
30. Bredy, T.W., *et al.* Histone modifications around individual BDNF gene promoters in prefrontal cortex are associated with extinction of conditioned fear. *Learning & memory (Cold Spring Harbor, N.Y.)* **14**, 268-276 (2007).
31. Roth, T.L., Lubin, F.D., Funk, A.J. & Sweatt, J.D. Lasting epigenetic influence of early-life adversity on the BDNF gene. *Biol Psychiatry* **65**, 760-769 (2009).
32. Lubin, F.D., Roth, T.L. & Sweatt, J.D. Epigenetic regulation of BDNF gene transcription in the consolidation of fear memory. *The Journal of neuroscience : the official journal of the Society for Neuroscience* **28**, 10576-10586 (2008).
33. Chen, E.S., Ernst, C. & Turecki, G. The epigenetic effects of antidepressant treatment on human prefrontal cortex BDNF expression. *Int J Neuropsychopharmacol* **14**, 427-429 (2011).
34. Lopez, J.P., *et al.* Epigenetic regulation of BDNF expression according to antidepressant response. *Mol Psychiatry* (in press).
35. Beech, R. Differences in peripheral blood gene-expression as predictors of response to treatment with lithium in subjects with bipolar disorder. *Biological Psychiatry* **63**, 222S-301S (2008).
36. Kalman, J., *et al.* Impact of venlafaxine on gene expression profile in lymphocytes of the elderly with major depression--evolution of antidepressants and the role of the "neuro-immune" system. *Neurochem Res* **30**, 1429-1438 (2005).
37. Mamdani, F., *et al.* Gene expression biomarkers of response to citalopram treatment in major depressive disorder. *Transl Psychiatry* **1**, 1-8 (2011).
38. Gavin, D.P., Chase, K.A. & Sharma, R.P. Enhancement of psychotherapy using epigenetic modulating drugs. *Medical hypotheses* **77**, 121-124 (2011).
39. Turecki, G., Ernst, C., Jollant, F., Labonte, B. & Mechawar, N. The neurodevelopmental origins of suicidal behavior. *Trends in neurosciences* **35**, 14-23 (2012).
40. Svenningsson, P. & Greengard, P. p11 (S100A10)--an inducible adaptor protein that modulates neuronal functions. *Current opinion in pharmacology* **7**, 27-32 (2007).

41. Melas, P.A., *et al.* Antidepressant treatment is associated with epigenetic alterations in the promoter of P11 in a genetic model of depression. *The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)*, 1-11 (2011).
42. Elliott, E., Ezra-Nevo, G., Regev, L., Neufeld-Cohen, A. & Chen, A. Resilience to social stress coincides with functional DNA methylation of the Crf gene in adult mice. *Nature neuroscience* **13**, 1351-1353 (2010).
43. Perkins, D.O., *et al.* microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. *Genome Biol* **8**, R27 (2007).
44. Mellios, N., Huang, H.S., Grigorenko, A., Rogaev, E. & Akbarian, S. A set of differentially expressed miRNAs, including miR-30a-5p, act as post-transcriptional inhibitors of BDNF in prefrontal cortex. *Hum Mol Genet* **17**, 3030-3042 (2008).
45. Zhou, R., *et al.* Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. *Neuropsychopharmacology* **34**, 1395-1405 (2009).
46. Chen, H., Wang, N., Burmeister, M. & McInnis, M.G. MicroRNA expression changes in lymphoblastoid cell lines in response to lithium treatment. *Int J Neuropsychopharmacol*, 1-7 (2009).
47. Baudry, A., Mouillet-Richard, S., Schneider, B., Launay, J.M. & Kellermann, O. miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. *Science (New York, N. Y.)* **329**, 1537-1541 (2010).
48. Lam, R.W., *et al.* Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. *J Affect Disord* **117 Suppl 1**, S26-43 (2009).
49. Gu, H., *et al.* Preparation of reduced representation bisulfite sequencing libraries for genome-scale DNA methylation profiling. *Nature protocols* **6**, 468-549 (2011).
50. Elliott, E., Ezra-Nevo, G., Regev, L., Neufeld-Cohen, A. & Chen, A. Resilience to social stress coincides with functional DNA methylation of the Crf gene in adult mice. *Nature Neuroscience* **13**, 1351-1354 (2010).
51. Grskovic, M., Javaherian, A., Strulovici, B. & Daley, G.Q. Induced pluripotent stem cells--opportunities for disease modelling and drug discovery. *Nature reviews. Drug discovery* **10**, 915-929 (2011).
52. Brennand, K.J., *et al.* Modelling schizophrenia using human induced pluripotent stem cells. *Nature* **473**, 221-225 (2011).
53. Dobbin, K.K. & Simon, R.M. Sample size planning for developing classifiers using high-dimensional DNA microarray data. *Biostatistics* **8**, 101-117 (2007).
54. Sonnenberg, F.A. & Beck, J.R. Markov models in medical decision making: a practical guide. *Medical decision making : an international journal of the Society for Medical Decision Making* **13**, 322-338 (1993).
55. Guidelines for the economic evaluation of health technologies: Canada. (ed. C.A.f.D.a.T.i. Health) (Ottawa, 2006).
56. Pyne, J.M., Tripathi, S., Williams, D.K. & Fortney, J. Depression-free day to utility-weighted score: is it valid? *Medical care* **45**, 357-362 (2007).
57. Lesage, A.D., *et al.* Prevalence of Mental Illnesses and Related Service Utilisation in Canada : An analysis of the Canadian Community Health Survey. (2006).
58. Beck, C.A., *et al.* Antidepressant utilization in Canada. *Soc Psych Psych Epid* **40**, 799-807 (2005).
59. Mamdani, M., Rapoport, M., Shulman, K.I., Herrmann, N. & Rochon, P.A. Mental health-related drug utilization among older adults - Prevalence, trends, and costs. *Am J Geriatr Psychiatry* **13**, 892-900 (2005).

60. Régie de l'assurance maladie du Québec & Régie de l'assurance maladie du Québec. Direction des services à la clientèle professionnelle. *Manuel des médecins spécialistes : régime d'assurance-maladie* (la Régie, Service de l'information aux professionnels, Québec, 2006).
61. Régie de l'assurance maladie du Québec. Liste des médicaments. (Régie de l'assurance maladie du Québec, Québec, 2012).
62. Yatham, L.N., *et al.* Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. *Bipolar Disord* **11**, 225-255 (2009).
63. Davis, D., *et al.* The case for knowledge translation: shortening the journey from evidence to effect. *BMJ* **327**, 33-35 (2003).
64. Pathman, D.E., Konrad, T.R., Freed, G.L., Freeman, V.A. & Koch, G.G. The awareness-to-adherence model of the steps to clinical guideline compliance. The case of pediatric vaccine recommendations. *Medical care* **34**, 873-889 (1996).
65. Green, L., Kreuter, M. & Deeds, S. *Health education planning: a diagnostic approach* (Mayfield Press, Palo Alto California, 1980).